10-Q: Utah Medical Products Reports Q3 Decline Amid Trade Headwinds

Utah Medical Products Inc. reported a significant drop in Q3 and nine-month net income and sales, primarily due to foreign trade events and distributor cancellations, leading to a revised full-year sales outlook.

Summary

• Net sales for Q3 2025 decreased by 1.9% to $9.81 million from $10.01 million in Q3 2024.
• Nine-month 2025 net sales fell by 7.2% to $29.48 million compared to $31.75 million in the same period of 2024.
• Net income for Q3 2025 was $2.63 million, a 26.2% decrease from $3.56 million in Q3 2024.
• Nine-month 2025 net income decreased by 20.5% to $8.72 million from $10.97 million in 2024.
• Diluted EPS for Q3 2025 was $0.82, down 19.9% from $1.02 in Q3 2024.
• Diluted EPS for the nine months ended September 30, 2025, was $2.68, a 13.5% decrease from $3.10 in 2024.
• The company recorded a $395,000 bad debt expense in Q3 2025 due to a cancellation fee invoiced to its China distributor for a non-cancellable order.
• Domestic U.S. sales increased by 3.0% in Q3 2025, while Outside U.S. (OUS) sales decreased by 8.5%.
• Cash and investments increased to $84.27 million as of September 30, 2025, from $82.98 million at December 31, 2024.
• The company repurchased 130,984 shares for $7.36 million in the first nine months of 2025, and paid $3.01 million in dividends.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant declines in sales and profitability, a downward revision of the full-year sales outlook, and specific negative events like distributor cancellations and bad debt expense. While the company maintains strong liquidity and continues share repurchases, these positives are overshadowed by the operational and financial underperformance relative to the prior year.

Positives

• Domestic U.S. sales showed resilience, increasing by 3.0% in Q3 2025 and direct other device sales were up 7.7% in Q3 and 9.8% in 9M 2025.
• Direct Filshie device sales increased by 16.5% in Q3 2025 and 7.5% in 9M 2025, partially offsetting declines in other areas.
• The company maintains a strong cash and investments balance of $84.27 million, an increase of $1.29 million since year-end 2024.
• Continued share repurchases, totaling $7.36 million for 130,984 shares in 9M 2025, demonstrate management's belief in the stock's value and return cash to shareholders.
• Litigation expenses for Filshie product liability claims were lower in both Q3 and 9M 2025 compared to the same periods in 2024, with a majority of cases dismissed.
• Research & Development expenses were $235,000 lower in 9M 2025 due to the completion of independent testing and validation of new biopharmaceutical high-pressure monitoring devices.
• The significant Femcare IIA amortization expense, representing over 5% of current revenues, is set to conclude in March 2026, which will improve future operating income margins.

Negatives

• Overall net sales declined by 1.9% in Q3 2025 and 7.2% in 9M 2025, primarily due to foreign trade events and distributor cancellations.
• Net income decreased substantially by 26.2% in Q3 2025 and 20.5% in 9M 2025.
• Operating income declined by 21.9% in Q3 2025 and 16.0% in 9M 2025, with operating income margin falling to 26.6% and 30.4% respectively.
• A $395,000 bad debt expense was recognized in Q3 2025 due to the cancellation of a non-cancellable order by a China distributor, impacting operating income.
• Sales to the previous major OEM customer, PendoTECH, continued to decline significantly, down $194,000 in Q3 2025 and $1.99 million in 9M 2025.
• Gross profit margin decreased to 57.1% in Q3 2025 and 56.8% in 9M 2025, affected by lower sales absorption of fixed manufacturing overhead and U.S. tariffs.
• U.S. tariffs on medical device imports from Ireland, particularly for Filshie devices, increased manufacturing costs and necessitated price increases to U.S. medical facilities.
• Return on Stockholder Equity (ROE) before dividends decreased to an annualized 10% in 9M 2025 from 12% in 9M 2024 due to lower net income.

Risks

• Foreign currency exchange rate fluctuations can materially affect the company's financial condition and operating results, as a significant portion of sales and operations are outside the U.S.
• Product liability lawsuits, specifically related to the Filshie clip, continue to be a factor, although most cases have been dismissed and the company does not expect the outcome of remaining litigation to be material.
• Dependence on OUS distributors carries risks, as evidenced by the recent cancellation or delay of non-changeable orders, leading to lost revenues and bad debt expense.
• Geopolitical and trade policies, such as U.S. tariffs on medical device imports, can increase costs, reduce margins, and necessitate price increases, potentially impacting customer demand.
• General business risks, as detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, could adversely affect the company's business, financial condition, and operating results.

Future Outlook

Management has revised its full-year 2025 consolidated sales expectation to be 6-7% lower than in 2024, a downward adjustment from the initial 5% projection, primarily due to changed demand from OUS distributors and weaker OUS economic conditions. Despite this, the company anticipates full-year 2025 EPS to be in the range of $3.40-$3.50 and adjusted consolidated EBITDA to be between $17 million and $18 million. The company plans to continue exploiting its biopharmaceutical high-pressure monitoring devices, leveraging OUS distribution, defending the Filshie Clip System, introducing new products, and seeking accretive acquisition opportunities, while continuing to return cash to stockholders through dividends and share repurchases if the stock is undervalued.

Management Comments

• "UTMDs 3Q 2025 financial performance was unusually affected by foreign trade events: i.e., the cancellation or possible delay of non-changeable/non-cancellable orders by two outside the U.S. (OUS) distributors."
• "If the cancellation fee is not paid, it is unlikely that there will be a future business relationship [with the China distributor]."
• "Management now expects that total annual 2025 consolidated sales may be about 7% lower compared to 2024, instead of the beginning of year 5% projection."
• "The significant Femcare IIA amortization expense, representing more than 5% of current revenues, will end in 1Q 2026 after 15 years."
• "The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders."
• "Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans."
• "If there are no better strategic uses for UTMDs cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued."

Industry Context

The medical device industry is experiencing shifts influenced by global trade policies, such as tariffs, which directly impact supply chains and pricing strategies for companies like Utah Medical Products. The company's strategic focus on expanding into the biopharmaceutical high-pressure monitoring device market indicates an effort to diversify revenue streams and capitalize on growth opportunities within specialized healthcare sectors, while navigating challenges in traditional markets like gynecology/electrosurgery and blood pressure monitoring. The decline in OUS sales suggests broader economic headwinds or increased competition in international markets.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or industry benchmarks to assess the results against global standards. Therefore, a direct comparison is not feasible based solely on the provided information.

Legal Proceedings

• The company is a party to Filshie clip U.S. product liability lawsuits, though most have received dismissals.
• The company does not expect the outcome of the remaining Filshie clip litigation to be material to consolidated financial results.

Stakeholder Impact

• Shareholders: Experienced lower EPS, but benefited from continued cash dividends and share repurchases, which helped mitigate the EPS decline.
• Customers (U.S. medical facilities): Faced price increases on Filshie devices due to U.S. tariffs on imports from Ireland, potentially impacting patient costs.
• OUS Distributors: The relationship with the China distributor is at risk due to a cancelled order and unpaid cancellation fee, potentially leading to termination of future business.
• Employees: Stock-based compensation expense increased, and headcount and salaries did not appreciably increase despite higher health plan costs.

Next Steps

• Exploit pre-qualified status to introduce a line of high-pressure process control transducer configurations directly to biopharmaceutical manufacturers.
• Continue to leverage OUS distribution and manufacturing synergies by further integrating capabilities and resources in multinational operations.
• Focus on defending the proven safety and effectiveness of the Filshie Clip System in the U.S.
• Introduce additional products helpful to clinicians through product development.
• Continue to achieve excellent overall financial operating performance despite a contraction in revenues.
• Utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/when the UTMD share price seems undervalued.
• Remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult economic conditions on small, innovative companies.
• Completion of Femcare IIA amortization in March 2026.

Key Dates

Recommendation

While Utah Medical Products demonstrates strong liquidity, a commitment to returning capital to shareholders through dividends and buybacks, and strategic initiatives in the biopharmaceutical sector, the recent financial performance shows significant declines in sales and profitability. The downward revision of the full-year sales outlook and the impact of foreign trade events and tariffs present notable headwinds. The stock's EPS decline was mitigated by share repurchases, suggesting management is actively trying to support shareholder value. However, until there's clear evidence of a turnaround in revenue growth and improved operating margins, particularly in OUS markets, a 'hold' recommendation is prudent. Investors should monitor the effectiveness of new product introductions and the resolution of trade-related challenges.

Keywords

Medical Devices, SEC Filing, 10-Q, Financial Results, Earnings, Sales, Profit Margins, Share Repurchases, Dividends, Foreign Exchange, Tariffs, Product Liability, Biopharmaceutical, Corporate Governance, UTMD